Ten-year outcomes of the russian drug-eluting stent Calypso in patients with acute coronary syndrome: data from a prospective multicenter study
https://doi.org/10.52727/2078-256X-2025-21-4-394-400
Abstract
Objective – to evaluate the long-term (10-year) safety and efficacy outcomes of the domestic sirolimus-eluting stent Calypso compared with the Xience Prime stent in patients with acute coronary syndrome (ACS) under real-world clinical conditions.
Material and methods. A total of 274 patients with ACS were initially enrolled in this prospective multicenter study. Patients were divided into two groups: the first group included 140 patients who received the Calypso stent, and the second group included 134 patients who received the Xience Prime stent. At the 10-year follow-up, complete data were available for 191 patients (69.7 %): 98 in the Calypso group and 93 in the Xience Prime group. The primary endpoint was the composite rate of major adverse cardiac events (MACE).
Results. Over the 10-year follow-up period, the incidence of MACE was 31.6 % in the Calypso group versus 34.4 % in the Xience Prime group (hazard ratio [HR] 0.91; 95 % confidence interval [CI] 0.58–1.43; p = 0.68). No statistically significant differences were observed between groups in any individual MACE components. The rate of restenosis requiring repeat stenting was 4.1 % and 7.5 % in the Calypso and Xience Prime groups, respectively (p = 0.29).
Conclusions. The Calypso sirolimus-eluting stent demonstrates long-term clinical efficacy and safety comparable to those of the Xience Prime stent in patients with acute coronary syndrome.
About the Authors
M. V. Chernyaev
RUDN University;
FGBU “NMIC TPM” of the Ministry of Health of Russia
Russian Federation
Russian Federation
Mikhail V. Chernyaev, candidate of medical scinces, associate professor of the department of hospital surgery with a course in pediatric surgery at the medical institute
6, Miklukho-Maklaya st., Moscow, 117198;
endovascular surgery
10, Bldg. 3, Petroverigsky Lane, Moscow, 101990
A. I. Zagorulko
State Budgetary Healthcare Institution, Oncology Center No. 1, City Clinical Hospital named after S.S. Yudin;
RUDN University
Russian Federation
Russian Federation
Alexei I. Zagorulko, сandidate of medical sciences, head of the department of X-ray surgical methods of diagnostics and treatment No. 2
18A, Zagorodnoe sh., Moscow, 117152;
physician in X-ray endovascular diagnostics and treatment, cardiovascular surgeon, assistant of the department of cardiology, X-ray endovascular and hybrid methods of diagnostics and treatment
6, Miklukho-Maklaya st., Moscow, 117198
A. A. Logunova
RUDN University
Russian Federation
Russian Federation
Anastasiya A. Logunova
6, Miklukho-Maklaya st., Moscow, 117198
V. A. Mityashina
RUDN University
Russian Federation
Russian Federation
Viktoria A. Mityashina
6, Miklukho-Maklaya st., Moscow, 117198
References
1. Byrne R.A., Rossello X., Coughlan J.J., Barbato E., Berry C., Chieffo A., Claeys M.J., Dan G.A., Dweck M.R., Galbraith M., Gilard M., Hinterbuchner L., Jankowska E.A., Jüni P., Kimura T., Kunadian V., Leosdottir M., Lorusso R., Pedretti R.F.E., Rigopoulos A.G., Rubini Gimenez M., Thiele H., Vranckx P., Wassmann S., Wenger N.K., Ibanez B. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2023; 44 (38): 3720–3826. doi: 10.1093/eurheartj/ehad191
2. Chernyaev M.V., Faibushevich A.G., Zagorul’ko A.I., Samochatov D.N., Kurtasov D.S., Verin V.V., Prokhorikhin A.A., Boikov A.A., Malaev D.U., Zobov V.V. Long-term results of using domestic drug-eluting stent in patients with acute coronary syndrome. Patologiya krovoobrashcheniya i kardiokhirurgiya. 2019; 23 (1 Suppl. 1): S52–S61. (In Russ.). doi: 10.21688/1681-3472-2019-1S-S52-S60
3. Chernyaev M.V., Faibushevich A.G., Muzganova Yu.S. Endovascular treatment of patients with acute coronary syndrome using stents with a limus-releasing coating. Zhurnal im. N.V. Sklifosovskogo. Neotlozhnaya meditsinskaya pomoshch’. 2019; 8 (1): 45–52. (In Russ.)]. doi: 10.23934/2223- 9022-2019-8-1-45-52
4. Chernyaev M.V., Zagorul’ko A.I., Kurtasov D.S., Faibushevich A.G., Koledinskii A.G. Immediate and mid-term results of the use of the drugcoated Calypso stent in acute coronary syndrome. Zhurnal Diagnosticheskaya i interventsionnaya radiologiya. 2017; 11(4): 42–47 (In Russ.)]. doi: https://doi.org/10.25512/DIR.2017.11.4.05
5. Fong S.H., Ford I., Jüni P., Berry B., da Costa R.O.C. Bias and Lossto Follow-Up in Cardiovascular Randomized Trials: A Systematic Review. J. Am. Heart Associat. 2020; 9 (14): e015361. doi: 10.1161/JAHA.119.015361
6. Brugaletta S., Ortega-Paz L.F., Rhode P., Sabaté M., Cequier A., Escolà-Gil J.C., Peruga J.L., García Del Blanco B., Garcia-Touchard A., Masotti M., RodríguezLeor O., González-Salvado V., Dalmau R., SerraA., Soler N., García-Picart J., Morata-Barrado G., Goicolea J., LópezBescós L. 10-Year Follow-Up of Patients With EverolimusEluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. J. Am. Coll. Cardiol. 2021; 77 (9): 1165–1178. doi: 10.1016/j.jacc.2020.12.059
7. Starnecker F., Yamaji K., Vranckx P., Ten Berg J.M., Tonino P.A.L., Wildgruber M., Witzenbichler B., Zeller T., Höke H., Rothenburger C., Bett V., Nef H.M., Ott I., Silber S., Härle T., Schäufele D., Laun M., Schneider S., Seubert P., Richardt G. Ten-year clinical outcomes after drug-eluting stents implantation according to clinical presentation – Insights from the DECADE cooperation. Eur. J. Clin. Invest. 2025; 55 (1): e14323. doi: 10.1111/eci.14323
8. Tanabe Y., Kuramitsu S., Shinozaki N., Tsujita K., Horiuchi R., Yui K., Suesada H., Beppu T., Yamaguchi T., Nakamura K., Muto S., Yamamoto E., Terada K., Kimura T., Tanaka Y., Matsukawa T., Mizoguchi T., Tsuji S., Yajima J., Isomura T., Kodama A., Nishio Y., Okuyama K., Tanaka H., Asahara H., Takahashi M., Kimura K. Long-term (beyond 5 years) clinical impact of Xience everolimus-eluting stent implantation. Health Sci. Rep. 2021; 4 (3): e365. doi: 10.1002/hsr2.365
9. Kimura T., Morimoto T., Natsuaki Y., Shiomi H., Toriumi Y., Nishikawa H., Tsukahara R., Nishimura K., Nakamura S., Yamamoto K., Makino N., Ito Y., Tsuji A., Nakazato Y., Tanaka N., Takatsu Y., Tsuchikane E., Chieffo A. Ten-year clinical outcomes from a randomized trial comparing newgeneration everolimus-eluting stent versus first-generation sirolimus-eluting stent: Results from the RESET extended study. Catheter. Cardiovasc. Interv. 2023; 112(5): 835–844. doi: 10.1002/ccd.30791
10. van der Heijden L.C., Stoel M.G., Danse P.W., Quint W.J., de Vries A.G., Sjauw K.D., Hirsch A., van der Ploeg T., Jewbali L.S.,MeuwissenM., HenriquesJ.P.S.Ten-Year FollowUp After Contemporary Percutaneous Coronary Intervention: The DUTCH PEERSTrial. JACC Cardiovasc. Interv. 2020; 13 (15): 1756–1765. doi: 10.1016/j.jcin.2020.04.051
11. Ruseckaite R., Mudunna C., Caruso M., Ahern S. Response rates in clinical quality registries and databases that collect patient reported outcome measures: a scoping review. Health Qual. Life Outcomes. 2023; 21 (1): 71. doi: 10.1186/s12955-023-02155-5
12. Rodriguez F., Maron D.J., Knowles J.W., Virani S.S., Lin S., Heidenreich P.A. Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019;4(2):123–130. doi:10.1001/jamacardio.2018.4772
Review
For citations:
Chernyaev M.V., Zagorulko A.I., Logunova A.A., Mityashina V.A. Ten-year outcomes of the russian drug-eluting stent Calypso in patients with acute coronary syndrome: data from a prospective multicenter study. Ateroscleroz. 2025;21(4):394-400. (In Russ.) https://doi.org/10.52727/2078-256X-2025-21-4-394-400
Views:
42
JATS XML
Email this article 
